Medical Condition News

RSS

Embryonic stem cells raise hope of cellular replacement therapy for liver failure

Embryonic stem (ES) cells, known for their capacity to proliferate indefinitely and differentiate into almost all types of cells including hepatocytes, have raised the hope of cellular replacement therapy for liver failure. There have been several protocols available for hepatic fate specification from ES cells, however, most of the protocols currently used result in low yield or purity of functional hepatocytes. Valproic acid (VPA), a histone deacetylase inhibitor, has been demonstrated to facilitate the hepatic differentiation of mesenchymal stem cells. However, little is know about whether VPA could induce the hepatic differentiation of ES cells.

19 Nov 2009

EIN News launches "Mesothelioma News Today"

EIN News, an online leader in industry news monitoring and press syndication, has today added a new publication to its portfolio of health-related international news sites for industry professionals and analysts: Mesothelioma News Today (http://mesothelioma.einnews.com).

19 Nov 2009

IASLC staging classification: A new approach to evaluate and treat lung cancers

The International Association for the Study of Lung Cancer (IASLC) will hold an expert roundtable and Web cast announcing the recent publication and impact of the IASLC's Staging Manual in Thoracic Oncology containing the recently released 7th Edition of TNM in Lung and Pleural Tumours.

19 Nov 2009

Astellas Pharma and XenoPort submit NDA in Japan for PMDA approval

Astellas Pharma Inc. and XenoPort, Inc. today announced that a new drug application (NDA) has been filed with the Pharmaceuticals and Medical Device Agency (PMDA) in Japan for ASP8825 (gabapentin enacarbil), also known as XP13512, as a potential treatment for restless legs syndrome (RLS).

19 Nov 2009

Updated clinical guidelines on Effient treatment for ACS patients

Effient® (prasugrel) tablets, a new antiplatelet medicine, was added as a treatment option in two clinical guideline updates: one for patients receiving percutaneous coronary intervention (PCI) and a second one for patients with ST elevation myocardial infarction (STEMI), or severe heart attack.

19 Nov 2009

Treatment of iron deficiency can improve symptoms and quality of life in CHF patients

Intravenous (I.V.) iron treatment with ferric carboxymaltose to reverse iron deficiency can significantly improve symptoms, exercise tolerance and quality of life for chronic heart failure (CHF) patients, researchers said in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009.

19 Nov 2009

Continuous flow heart pump improves survival rates in heart failure patients than current pulsating models

A new, continuous flow heart pump, or left ventricular assist device (LVAD), delivered better two-year survival in advanced heart failure patients than the current pulsatile model, researchers reported in a late-breaking clinical trial presentation at the American Heart Association's Scientific Sessions 2009.

19 Nov 2009

OA panel develops a consensus of the optimal exogenous HA treatment using BioRestorative Profiling

A panel of osteoarthritis (OA) key opinion leaders has developed a consensus of the optimal exogenous hyaluronic acid (HA) treatment. This consensus was achieved by utilizing what the experts referred to as BioRestorative(TM) Profiling. This profiling examines HAs on the basis of their mimicking the body's natural HA.

19 Nov 2009

UCLA study: Structural changes in brain may help offset vision loss and strengthen other senses

Visually impaired people appear to be fearless, navigating busy sidewalks and crosswalks, safely finding their way using nothing more than a cane as a guide. The reason they can do this, researchers suggest, is that in at least some circumstances, blindness can heighten other senses, helping individuals adapt.

19 Nov 2009

Microarray analysis can identify chromosome abnormalities in children with Pitt-Hopkins syndrome

Researchers at Signature Genomic Laboratories, which performs diagnostic genetic testing of chromosome abnormalities in individuals with unexplained physical and developmental disabilities, recently showed that microarray analysis can identify small DNA alterations in individuals with Pitt-Hopkins syndrome, a rare and poorly characterized genetic disorder.

19 Nov 2009

System to help identify patients at high risk of developing delirium

A specialist in caring for elderly patients, Turner-Hubbard is a geriatric nurse practitioner trained to quickly spot the sudden changes in mental status that signal the onset of the sudden, severe confusion known as delirium. She knows the hospital “triggers” that can bring on fluctuations in behavior: blood loss during surgery, anesthesia, pain medications and anti-anxiety drugs, infections, dehydration, IV lines and catheters, as well as being immobilized for an extended period of time.

19 Nov 2009

NeuroRehabilitation: A one-stop resource for persons with neurodisabilities

IOS Press announces the November 2009 publication of a special issue of NeuroRehabilitation: An International Journal devoted to residential design for persons with neurodisability.

19 Nov 2009

Report on unexplained liver haemorrhage after metastasis radiofrequency ablation published

Colorectal carcinoma is one of the most common cancers in the world. Approximately one in four of these patients have metastases at diagnosis, liver being the most common site involved. Although historically it was considered that liver metastases meant a very poor prognosis, today, due to improved systemic therapy, many patients will be candidates for local hepatic treatments such as surgery or less aggressive radiofrequency ablation.

19 Nov 2009

AFFiRiS to commence Phase II trial of its Alzheimer's vaccine candidate

AFFiRiS AG will focus its Alzheimer's vaccine program on one product candidate at an unexpectedly early stage of development: the vaccine candidate AD02 is planned to enter into Phase II clinical trial early in 2010. This decision by the company immediately follows the completion of two Phase I trials with the candidates AD01 and AD02. The company based its fast decision on the first interim analysis of the secondary endpoints at the six month time point.

19 Nov 2009

New report finds positive association between phthalate exposure and ADHD symptoms

Phthalates are important components of many consumer products, including toys, cleaning materials, plastics, and personal care items. Studies to date on phthalates have been inconsistent, with some linking exposure to these chemicals to hormone disruptions, birth defects, asthma, and reproductive problems, while others have found no significant association between exposure and adverse effects.

19 Nov 2009

Possible new approach to slow the progression of cognitive decline in Down's syndrome

A study by neuroscientist William C. Mobley, MD, PhD, chair of the Department of Neurosciences at the University of California, San Diego School of Medicine, and colleagues at Stanford University Medical School has demonstrated a possible new approach to slowing the inevitable progression of cognitive decline found in Down's syndrome.

19 Nov 2009

Diagnosing patients with syndrome similar to neurofibromatosis type 1 may be difficult

An analysis of patients with a syndrome similar to the genetic disorder, neurofibromatosis type 1, indicates that diagnosis may be difficult because of shared clinical findings, such as certain pigmentary characteristics, according to a study in the November 18 issue of JAMA.

19 Nov 2009

USP releases new CRMs for carbamazepine, phenytoin, and theophylline

To help bring greater certainty to the measurement of medication levels in a patient's bloodstream for three drugs with narrow therapeutic ranges, the U.S. Pharmacopeial Convention (USP) is releasing new certified reference materials (CRMs).

19 Nov 2009

Reduction of serum bilirubin, the hallmark of successful biliary drainage

Biliary drainage is performed as a palliative treatment of hilar cholangiocarcinoma. The reduction of serum bilirubin is usually the hallmark of successful biliary drainage. However, some patients may have persistent jaundice or scanty bile output after biliary drainage.

19 Nov 2009

BIMR wins a GO grant from the National Institute of Mental Health

Thanks to a $50,000 grant from the California Bipolar Foundation (CBF) to post-doctoral research fellow Dr. Illyas Singec at the Burnham Institute for Medical Research (BIMR), a research team headed by Dr. Evan Snyder (along with co-investigators Drs. Dieter Wolfe and Lawrence Brill), was able to accumulate sufficient preliminary data to win an extremely competitive Grand Opportunities (GO) grant from the National Institute of Mental Health to explore the molecular basis of Bipolar Disorder (BPD).

19 Nov 2009

Medical Condition News

Embryonic stem cells raise hope of cellular replacement therapy for liver failure

EIN News launches "Mesothelioma News Today"

IASLC staging classification: A new approach to evaluate and treat lung cancers

Astellas Pharma and XenoPort submit NDA in Japan for PMDA approval

Updated clinical guidelines on Effient treatment for ACS patients

Treatment of iron deficiency can improve symptoms and quality of life in CHF patients

Continuous flow heart pump improves survival rates in heart failure patients than current pulsating models

OA panel develops a consensus of the optimal exogenous HA treatment using BioRestorative Profiling

UCLA study: Structural changes in brain may help offset vision loss and strengthen other senses

Microarray analysis can identify chromosome abnormalities in children with Pitt-Hopkins syndrome

System to help identify patients at high risk of developing delirium

NeuroRehabilitation: A one-stop resource for persons with neurodisabilities

Report on unexplained liver haemorrhage after metastasis radiofrequency ablation published

AFFiRiS to commence Phase II trial of its Alzheimer's vaccine candidate

New report finds positive association between phthalate exposure and ADHD symptoms

Possible new approach to slow the progression of cognitive decline in Down's syndrome

Diagnosing patients with syndrome similar to neurofibromatosis type 1 may be difficult

USP releases new CRMs for carbamazepine, phenytoin, and theophylline

Reduction of serum bilirubin, the hallmark of successful biliary drainage

BIMR wins a GO grant from the National Institute of Mental Health

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Latest News